BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept
June 12, 2017 at 16:42 PM EDT
* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.